Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACLE: Adalimumab and Methotrexate Dosage in Rheumatoid Arthritis
NCT03505008Phase 4Completed
- Sponsor
- Keio University
- Start
- Apr 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of adalimumab in rheumatoid arthritis (RA), sponsored by Keio University. Started Apr 2018; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03505008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505008.